Business Wire

Semifinalist Teams Selected in $10M ANA Avatar XPRIZE Competition

Share

XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, announced today that 38 teams from 16 countries are advancing to the semifinals round of the $10M ANA Avatar XPRIZE competition.

Sponsored by All Nippon Airways (ANA), Japan’s largest airline, the Avatar XPRIZE is a four-year global competition focused on the development of an avatar system that will deploy a human’s senses, actions, and presence to a remote location in real time, leading to a more connected world. These avatars must demonstrate the ability to execute tasks across a variety of real-world scenarios and convey a sense of presence for both the operator and the recipient in those interactions. In the future, avatars could help provide critical care and deploy immediate responses in emergency situations, or offer opportunities for exploration and new ways of collaboration, stretching the boundaries of what is possible and maximizing the impact of skill and knowledge sharing.

“We are rapidly approaching an era where it will be possible for a doctor in New York to export their skillset virtually to respond to a natural disaster across the globe,” said Anousheh Ansari, CEO of XPRIZE. “The task at hand for these incredible semifinalist teams competing in the ANA Avatar XPRIZE is to break through physical limitations and expand the capacity of humankind itself through transformative robotic avatar technology.”

In February 2021, qualified teams completed their semifinalist selection submissions—the second round of technical submissions for evaluation by the judging panel. Each team submitted a comprehensive write-up detailing their avatar system's capabilities and their development plans, accompanied by a demonstration video showcasing their technology in action. The judges extensively reviewed the submissions and selected 38 semifinalists to advance out of the field of 77 qualified teams.

The ANA Avatar XPRIZE semifinalist teams are:

  • 1to1Robotics, Hackensack, New Jersey, United States
  • Aham, Bangalore, India
  • Augnition, Helsinki, Finland
  • AvaDynamics, Pittsburgh, Pennsylvania, United States
  • Avatar Quest, San Jose, California, United States
  • AVATRINA, Urbana, Illinois, United States
  • BellContinuous, Arlington, Texas, United States
  • Cyberselves, Sheffield, United Kingdom
  • Dragon Tree Labs, Moscow, Russia
  • ENZO AVATAR, Bucaramanga, Colombia
  • Forged Droids, Tempe, Arizona, United States
  • GITAI, Tokyo, Japan
  • H2L, Tokyo, Japan
  • Human Fusions, Cleveland, Ohio, United States
  • i-Botics, Utrecht, Netherlands
  • iCub, Genoa, Italy
  • Inbiodroid, Irapuato, Mexico
  • Janus, Tsukuba, Japan
  • Junnichi Suko, Tokyo, Japan
  • Kimaera Dynamics, Toronto, Canada
  • Last Mile – small world project 2, Osaka, Japan
  • Limitless, Lugano, Switzerland
  • NimbRo, Bonn, Germany
  • Pollen Robotics, Bordeaux, France
  • proRobot, Vysoké Mýto, Czech Republic
  • Rezilient, St. Louis, Missouri, United States
  • Robot Guru (HoloSuit), Mysuru, India
  • Robotics Services LLC, Providence, Rhode Island, United States
  • Roboy, Munich, Germany
  • Sant'Anna, Pisa, Italy
  • SYNAPSE, Tokyo, Japan
  • Team Northeastern, Boston, Massachusetts, United States
  • Team SNU, Ulsan, South Korea
  • Team UNIST, Seoul, South Korea
  • Telexistence, Tokyo, Japan
  • Touchlab, Edinburgh, United Kingdom
  • Virtual Sapiens, Chennai, India
  • X-Presence, Kobe, Japan

Additional details about all competing teams can be found here.

“The breakthroughs that will develop out of the ANA Avatar XPRIZE have the potential to entirely reimagine the human experience,” said David Locke, Executive Prize Director of ANA Avatar XPRIZE. "We’re thrilled to announce the semifinalist teams and are excited to put their technologies to the test, and experience their ability to transport our sense of presence, during semifinals testing this fall.”

"Now that the semifinalist teams have been chosen, we are one very important step closer to realizing our dream of revolutionizing human connection," said Mitsuo Tomita, Senior Vice President of Marketing at All Nippon Airways. "As a company whose mission it is to connect people, we are beyond excited to see the technology that will be developed by these 38 teams. We are eager to see the innovative ways in which the teams will light up our imaginations with visions of a future in which travel and human connection are limitless."

After the completion of semifinals testing in Fall 2021, up to 20 teams will equally split a Semifinals prize purse of $2M and move on to finals testing in Summer 2022. There, they will compete to win a share of the $8M finals prize purse.

The grand prize will be awarded in June 2022 after finals testing, which will include performance tests based on specific tasks that showcase the application of avatar technologies across several use case scenarios. The winning team will integrate multiple emerging technologies to develop a physical, nonautonomous avatar system with which an operator can see, hear, and interact within a remote environment in a manner that feels as if they are truly there.

The ANA Avatar Advisory Board has been integral in the competition since its launch in January 2019. The group consists of esteemed robotics experts, haptics inventors, psychology professors, top entertainment researchers, virtual world creators, computer vision dynamos and more. The full list of experts can be found below with additional information and bios available here.

For more information on the ANA Avatar XPRIZE, the semifinalist teams, and ANA, please visit avatar.xprize.org.

About XPRIZE

XPRIZE, a 501(c)(3) nonprofit organization, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $100 Million XPRIZE Carbon Removal with Elon Musk, $20 Million NRG COSIA Carbon XPRIZE, $15 Million XPRIZE Feed the Next Billion, $10 Million XPRIZE Rainforest, $10 Million ANA Avatar XPRIZE, $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling and $1M Digital Learning Challenge. For more information, visit xprize.org.

ABOUT ANA

Founded more than 60 years ago in 1952 with just two helicopters, All Nippon Airways (ANA), has become the largest airline in Japan, serving 46 international destinations and 50 domestic destinations.

ANA HOLDINGS Inc. (ANAHD) was established in 2013 as the largest airline group holding company in Japan comprised of 78 companies including ANA and Peach Aviation Limited, the leading LCC in Japan. The 78 companies organized under the ANAHD umbrella operate in a diverse range of markets, including air transportation, travel services and trade, and retail embody ANAHD’s shared values of exceptional service, responsible corporate citizenship and investment in the communities where they operate.

ANA is a launch customer and the biggest operator of the Boeing 787 Dreamliner, making ANAHD the biggest Dreamliner owner in the world. A member of Star Alliance since 1999, ANA has Joint Venture agreements with United Airlines, Lufthansa Airlines, Swiss International Airlines, Austrian Airlines and Brussels Airlines– giving it a truly global presence.

Supplementing its operations in commercial aviation, ANAHD has led the development of the innovative haptic robotics program, through its avatarin Inc. company, and its involvement in space with its partnership with JAXA, and other space related companies such as Astroscale and PD Aerospace.

The airline’s legacy of superior service has helped it earn SKYTRAX’s respected 5-Star rating every year since 2013, making ANA the only Japanese airline to win this prestigious designation and for eight consecutive years. ANA also has been recognized by Air Transport World as “Airline of the Year” three times (2007, 2013 and 2018); it is one of a select few airlines to win this prestigious award multiple times.

For more information, please refer to the following link:
https://www.ana.co.jp/group/en/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Caden Kinard, XPRIZE
caden.kinard@xprize.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 01:13:00 EET | Press release

Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 22:00:00 EET | Press release

Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar

SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 21:35:00 EET | Press release

SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support of the optics and photonics community and mentorship of others. “It’

Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 21:00:00 EET | Press release

Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 20:30:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST. HERIZON-GEA-01 met the dual primary endpoint of progression-free survival (PFS), demonstrating statistically significant and clinically meaningful improvements in both experimental arms compared to the control arm. The addition of TEVIMBRA to ZIIHERA and chemotherapy also sho

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye